Status:
TERMINATED
A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Kidney Transplantation
Delayed Graft Function
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
This research is being done to study the effects (good and bad) of taking CellCept based on blood concentrations versus taking a fixed dose of CellCept without measuring the blood concentration. CellC...
Detailed Description
This study is an open label study, which means the participant will know which drugs they are on. Participants will be put in one of three groups within 24 hours of the participant's transplant. The p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Participants must be between 18 and 70 years of age and should be receiving their first or second kidney transplant.
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00217152
Start Date
March 1 2005
End Date
August 1 2007
Last Update
December 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905